

IN THE CLAIMS

Claims 1-113 (canceled)

114. (new) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising insulin, a PKC α inhibitor, wherein the PKC α inhibitor consists of the myristoylated peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.

115. (new) A composition comprising insulin and a PKC α inhibitor of SEQ ID NO: 1.

116. (new) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.

117. (new) The pharmaceutical composition of claim 116, wherein said at least one additional agent is a growth factor.

118. (new) The pharmaceutical composition of claim 117, wherein said growth factor is a platelet-derived growth factor.

119. (new) The pharmaceutical composition of claim 116, wherein said at least one additional agent is a PKC- α inhibitor.

120. (new) The pharmaceutical composition of claim 116, wherein said insulin is recombinant insulin.

121. (new) The pharmaceutical composition of claim 116, wherein said insulin is of a natural source.

122. (new) The pharmaceutical composition of claim 116, adapted for topical application.

123. (new) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a single dose-unit of insulin selected capable of inducing or accelerating a healing process of the skin wound, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.

124. (new) The pharmaceutical composition of claim 123, wherein said single dose-unit of insulin is 0.001 to 5 nM in 0.01-0.2 ml of said pharmaceutical composition.

125. (new) The pharmaceutical composition of claim 123, wherein said single dose of insulin is ranging from 0.01 to 0.5 nM in 0.01-0.2 ml of said pharmaceutical composition.

126. (new) The pharmaceutical composition of claim 123, wherein said insulin is a recombinant.

127. (new) The pharmaceutical composition of claim 123, wherein said insulin is of a natural source.

128. (new) The pharmaceutical composition of claim 123, wherein said insulin is contained in a formulation adapted for topical application.

129. (new) The pharmaceutical composition of claim 128, wherein said formulation is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.

130. (new) An article of manufacture comprising the pharmaceutical composition of claim 129 applied on a solid support.